Abstract | PURPOSE: METHODS: RESULTS: Forty-nine eyes of 45 patients were collected. Mean visual acuity (VA) at baseline was 20/49 (range 20/20 - 5/200). Patients presented with IOI a mean of 24 (range 3-63) days after most recent brolucizumab injection; 61% presented for an unscheduled visit while 39% presented at routine follow-up. Mean VA at IOI presentation was 20/67 (range 20/20 - 3/200). Most common symptoms were floaters (78%) and blurry vision (76%). Pain (20%) and redness (16%) were less common; 3 (6%) eyes were asymptomatic. IOI was anterior only in 18%, posterior only in 31%, and both anterior and posterior in 51% of eyes. Treatment included topical steroids alone in 67% eyes, while 10% eyes received no treatment. Mean VA at last follow-up was 20/56 (range 20/20 - 1/200). Three (6%) eyes lost 3 or more lines and 1 (2%) eye lost 6 or more lines. CONCLUSIONS:
Brolucizumab-associated IOI without retinal vasculitis typically presented with a delayed onset of a few weeks. Often, visual acuity decline was relatively mild. Most symptoms resolved and nearly all had a return to baseline VA, but a small percentage of patients had a significant decrease in VA at last follow-up.
|
Authors | Andre J Witkin, Paul Hahn, Timothy G Murray, J Fernando Arevalo, Kevin J Blinder, Netan Choudhry, Geoff G Emerson, Roger A Goldberg, Stephen J Kim, Joel Pearlman, Eric W Schneider, Homayoun Tabandeh, Robert W Wong |
Journal | Journal of vitreoretinal diseases
(J Vitreoretin Dis)
Vol. 5
Issue 4
Pg. 326-332
(Jul 2021)
ISSN: 2474-1264 [Print] United States |
PMID | 34604691
(Publication Type: Journal Article)
|